Belite Bio Wins FDA Priority Review for Tinlarebant in Stargardt Disease
Belite Bio NASDAQ: BLTE said the U.S. Food and Drug Administration has accepted its new drug application for tinlarebant as a treatment for Stargardt disease type 1, granted the application priority review and set a Feb. 12, 2027, PDUFA date.
Belite Bio, Inc (BLTE) Discusses Prelaunch Strategy and Commercial Opportunity for Tinlarebant in Stargardt Disease Type 1 Transcript
Belite Bio, Inc (BLTE) Discusses Prelaunch Strategy and Commercial Opportunity for Tinlarebant in Stargardt Disease Type 1 Transcript
Belite Bio Q2 Earnings Call Highlights
Belite Bio NASDAQ: BLTE said the U.S. Food and Drug Administration has accepted its New Drug Application for tinlarebant, an investigational treatment for Stargardt disease, and granted the application priority review. The agency set a Prescription Drug User Fee Act action date of Feb. 12, 2027.
BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA
Belite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in February 2027 after positive phase III data.
Belite Bio: The Oral Route Is The Real Competitive Moat
Belite Bio (BLTE) is positioned for upside with tinlarebant, an oral therapy for Stargardt disease, following a successful Phase 3 DRAGON trial and NDA submission. BLTE's oral systemic approach offers competitive differentiation, enabling bilateral retinal treatment and potentially reducing the burden of frequent intravitreal injections. With $798.6 million in cash and investments, BLTE maintains a robust runway to support commercialization and further clinical development, including the PHOENIX trial in geographic atrophy.
Belite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal Diseases
Panelists at the H.C. Wainwright Sixth Annual Ophthalmology Virtual Conference said investigational therapies for inherited retinal disorders could begin to reshape treatment options for Stargardt disease and retinitis pigmentosa, two conditions with limited or no approved treatment choices today.
Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease
Belite Bio NASDAQ: BLTE Chief Medical Officer Hendrik Scholl said the company is advancing its lead compound, Tinlarebant, as a potential treatment for Stargardt disease and geographic atrophy secondary to age-related macular degeneration, two severe retinal diseases with overlapping features.
Belite Bio, Inc (BLTE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Belite Bio, Inc (BLTE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Belite Bio, Inc (BLTE) Q1 2026 Earnings Call Transcript
Belite Bio, Inc (BLTE) Q1 2026 Earnings Call Transcript
Belite Bio Q1 Earnings Call Highlights
Belite Bio NASDAQ: BLTE said it has begun a rolling New Drug Application submission to the U.S. Food and Drug Administration for Tinlarebant in Stargardt disease, while also accelerating preparations for a potential commercial launch.
Belite Bio, Inc (BLTE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Belite Bio, Inc (BLTE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Belite Bio, Inc (BLTE) Q4 2025 Earnings Call Transcript
Belite Bio, Inc (BLTE) Q4 2025 Earnings Call Transcript
